As drugs such as Ozempic, Rybelsus, and Wegovy continue to make the news for their abilities to treat diabetes and weight loss benefits, researchers are exploring other uses and side effects. In this faculty Q&A, Robert Fontana, M.D., a Michigan Medicine hepatologist, professor of medicine, and lead author of a new research letter, discusses the potential benefits and risks of these drugs for patients with liver disease.
